ÃâÒßѧÊÔÌâ
[w f12P Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
m##=iB|; 1. Fas(CD95)/FasL
3:Wr)>l}# 2. common chain of cytokine receptor
}3 }=tN5 3 . TCR/CD3 complex
Mk[`HEO 4. negaive selection of thymocytes
3iw9jhK!W 5. artificial active immune
1tW:(~=a; 6. anti-idiotypic
qS
al~ 7. IgSF
cmI#R1\ 8. Integrin
U@nwSfp:G 9. chemokine
Ziimz}WHF 10. B7/CD28
8BDL{?Mu ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
dL(|Y{4 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
-::%9D}P| 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
VKz<7K\/ 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
6l'y 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
->=++
uszSFe]E 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
-QDgr`%5 µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
uW=NH;u Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
C&kl*nO 1. B7/CD28
*(B[J 2. Th1 subset
T0%TeFY 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
_9|@nUD 4. antibody affinity maturation
yuEOQ\!(u 5. AP-1
30+l0\1 6. single chain variable fragment£¨ScFv£©
:
"te- 7. NK cell receptor
+t4m
\/y 8. Zinkernagel-Doherty phenomenon
9t.yP;j\Y 9. Ig fold
`e>F<{
M6@ 10. CD40/CD40L
gec T*^ ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
Cnci%eo 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
iLcadX 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
ZM`P~N1?)g 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
eZ5}O
0sfp Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
}, &,Dt 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
8:?Q(M7 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
:*:fun
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
XqS*;Zj0 Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
XW_xNkpL5c £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
H9Q7({v Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
?J@qg20z 1.Co-stimulators (or co-stimulating molecules)
S{i@=: 2.NK-kB
2vdQ&H4 3.Immunoglobulin superfamily
|4> r" 4.antigen-presenting cell (APC)
ZQ' z 5.death domain
a05:iFoJ 6.CCR and CXCR
dN\P&"` 7.Lectin (or mitogen)
DT"Zq
8.Clusters of differentiation, CD)
ElR&scXi__ 9.B7 family
W;oU +z^t$ 10.Cytotoxic T lymphocyte, CTL)
JRjMt-7H_ 11.IL-15 and IL-15 receptor (IL-15R)
D7WI(j\ 12.MHC restriction
K*U=;*p) 13.Affinity-chromatography
`TD%M`a 14.Cyctosprin A, CsA
?WQ
d 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
r;on0wm&B ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
a}qse5Fr 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
YUVc9PV)Ws 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
lc3
S|4 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
kV:FJx0xP Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
,KhMzE8_a ÃâÒßѧרҵ£º
tk)>CK11 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
2^^'t 6@ Ïû»¯ÄÚ¿Æ£º
,hTwNVWI9 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
mU3Y) ѪҺ²¡Ñ§×¨Òµ£º
*pb:9JKi 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
eC^0I78x Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
H#|Z8^ *Ds (רҵ»ù´¡: ÃâÒßѧ)
Cb
)= n6 Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
?zhI=1ED% 1. ADCC(antibody dependent cell-mediated cytotoxicity)
vTMP&a'5L 2. »·æß¾úËØ(cyclosporin)
9QOr,~~s 3. KIR(killer cell inhibitory receptor)
YV1a3 4. HLDA(human leucocyte differentiation antigen)
65waq~# 5. Interleukin 18(IL-18)
T@Ss&eGT2 6. ÕûºÏËØ(integrin)
e+F}9HR
7 7. Fas/FasL
/zl3&~4 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
K9C@dvFH 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
H]tSb//qc 10. Th1/Th2
b(|%Gbg@c 11. »ùÒòÒßÃç(DNAÒßÃç)
l$qStL*8O 12. chemokines and chemokine receptor
P1 7> 6)a 13. ÃâÒßÄÍÊÜ
&\"Y/b
] 14. ¹²´Ì¼¤·Ö×Ó
W+d9cM= 15. ËÀÍö½á¹¹Óò(death domain)
u}-d7-= ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
/'Quu)~ 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
.8T\Nr\~2 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
kZU
"Xn £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
o{{:|%m3Q £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
U OR _M
5 £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
A$9q!Ui#d £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
%r M-"6Q 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
}yx=(+jP Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
~a'nHy1 ÎÊ´ðÌâ(ÿÌâ25·Ö)
457fT | 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
2j8Cv:{Nn% 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
eZ!yPdgy| 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
W:VW_3 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£